Severe symmetric intrauterine growth retardation associated with the topical use of triamcinolone

doi:10.1016/0002-9378(90)90394-M

American Journal of Obstetrics and Gynecology

Volume 162, Issue 2, February 1990, Pages 396-397

https://doi.org/10.1016/0002-9378(90)90394-M Get rights and content

Triamcinolone acetonide, a fluorinated glucocorticoid, when given in large parenteral doses has produced structural anomalies and severe growth retardation in nonhuman primates. We present a case report of a gravid patient who applied 40 mg/day of triamcinolone cream because of atopic dermatitis from 12 to 29 weeks' gestation. The infant was symmetrically growth retarded, possibly from exposure to triamcinolone acetonide. There was no evidence of hypoxic, chromosomal, or infectious cause of the growth delay.

References (2)

TE Bunton et al.
Triamcinolone-induced structural alterations in the development of the lung of the fetal rhesus macaque
Am J Obstet Gynecol.
(1984)
AG Hendrickx et al.
Teratogenic effects of triamcinolone on the skeletal and lymphoid systems in nonhuman primates
Fed Proceed
(1975)

Cited by (36)

Dermatologic drugs during pregnancy and lactation
2012, Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and Print
Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases
2008, Journal of the American Academy of Dermatology
Citation Excerpt :
However, maternal use of topical corticosteroids from 4 weeks before through 12 weeks after conception was not associated with an increased risk of cleft lip ± cleft palate in a population-based case-control study.17 In a case report, severe intrauterine growth retardation was described in the infant of a woman who used an unusually large amount (40 mg/d) of topical triamcinolone after the 12th week of gestation.18 In practice, a conservative approach would warn pregnant women not to use large amounts of topical corticosteroids over extensive parts of the body because of the possibility of having a newborn with low birth weight.
In patients with psoriasis, there is an increased availability of drugs for treatment. However, there are important questions about drug safety for mothers with psoriasis and their fetuses. Currently, there are limited safety data for many of the medications used. In this article, we review current pregnancy risk information for medications commonly used in the treatment of psoriasis. In addition, a list of teratology information resources is included to help practicing clinicians find up-to-date information regarding the safety of the medications they prescribe.
The cosmetic use of skin-lightening products during pregnancy in Dakar, Senegal: a common and potentially hazardous practice
2007, Transactions of the Royal Society of Tropical Medicine and Hygiene
Many women of childbearing age from sub-Saharan Africa use topical skin lighteners, some of which present a risk of toxic systemic effects. The goals of this study were to evaluate, in this environment, the frequency of this practice during pregnancy, as well as eventual consequences on pregnancy. Ninety-nine women from 6 to 9 months pregnant were randomly selected among those attending a standard maternal centre in Dakar for a prenatal visit. Investigations consisted of questions about the use of skin lighteners, a standard clinical examination, follow-up until delivery and a morning blood sample for plasma cortisol levels. Sixty-eight of the 99 selected women used skin lighteners during their current pregnancy, the main active ingredients being hydroquinone and highly potent steroids (used by 64 and 28 women, respectively). No difference in the main outcomes of pregnancy were found between skin-lightener users and the others; however, women using highly potent steroids, when compared with those who did not, had a statistically significant lower plasma cortisol level and a smaller placenta, and presented a higher rate of low-birth-weight infants. Skin lightening is a common practice during pregnancy in Dakar, and the use of steroids may result in consequences in the mother and her child.
The Use of Dermatologic Drugs in Pregnancy and Lactation
2006, Dermatologic Clinics
Asthma management across the life span: The childbearing woman with asthma
2003, Nursing Clinics of North America
Safety of glucocorticoid administration during pregnancy
2003, Medicina Clinica

View all citing articles on Scopus

View full text

Severe symmetric intrauterine growth retardation associated with the topical use of triamcinolone

Am J Obstet Gynecol.

Teratogenic effects of triamcinolone on the skeletal and lymphoid systems in nonhuman primates

Fed Proceed